SCHEMBL24673985

SCHEMBL24673985

Nc1ncnc2c1ncn2[C@@H]1O[C@@]2(C[C@H]2OC(=O)c2ccccc2)C(O)C1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.58
▸ WDR77 Q9BQA1 1/20 0.58
▸ AHCY P23526 6/20 0.51
▸ P2RX3 P56373 2/20 0.51
▸ P2RX4 Q99571 2/20 0.51
▸ P2RX2 Q9UBL9 2/20 0.51
▸ ENPP1 P22413 1/20 0.51
▸ HIF1A Q16665 1/20 0.50
▸ TMEM97 Q5BJF2 1/20 0.50
▸ SIGMAR1 Q99720 1/20 0.50
▸ P2RX6 O15547 1/20 0.49
▸ P2RX1 P51575 1/20 0.49
▸ P2RX5 Q93086 1/20 0.49
▸ P2RY11 Q96G91 1/20 0.49
▸ P2RX7 Q99572 1/20 0.49
▸ PDE4A P27815 3/20 0.49
▸ PDE4B Q07343 3/20 0.49
▸ PDE4C Q08493 3/20 0.49
▸ PDE4D Q08499 3/20 0.49
▸ PDE3B Q13370 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24673102 1.00 PRMT5 (0.58) PRMT5WDR77AHCYP2RX3P2RX4
SCHEMBL22707421 0.87 PRMT5 (0.54) PRMT5WDR77AHCYP2RX3P2RX4
SCHEMBL24673581 0.81 PRMT5 (0.80) PRMT5WDR77AHCYHIF1ATMEM97
SCHEMBL24673580 0.81 PRMT5 (0.80) PRMT5WDR77AHCYHIF1ATMEM97
SCHEMBL24673475 0.81 PRMT5 (0.80) PRMT5WDR77AHCYHIF1ATMEM97
SCHEMBL24673136 0.81 PRMT5 (0.80) PRMT5WDR77AHCYHIF1ATMEM97
SCHEMBL22799204 0.80 AHCY (0.55) AHCYP2RX3P2RX4P2RX2ENPP1
SCHEMBL3365589 0.77 PRMT5 (0.46) PRMT5WDR77AHCYP2RX3P2RX4
SCHEMBL13046091 0.77 P2RX3 (0.66) P2RX3P2RX4P2RX2ENPP1HIF1A
SCHEMBL5797743 0.77 P2RX3 (0.66) P2RX3P2RX4P2RX2ENPP1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220275018-A1 NOVEL SPIROBICYCLIC INTERMEDIATES JANSSEN PHARMACEUTICA NV (BE) 2022-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220275018-A1 NOVEL SPIROBICYCLIC INTERMEDIATES NME2, SLC28A1, SLC28A2 PRMT5 3663/4885WDR77 3289/4885AHCY 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback